Clinical Trials · NCT05610800
Exenatide for Smoking Cessation and Prevention of Weight Gain
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- The University of Texas Health Science Center, Houston
- Enrollment
- 140
- Start date
- Dec 2022
- Locations
- 2 sites, United States
- Primary endpoint
- Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level